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Background: Major Depressive Disorder is a leading cause of disability, tends to run a recurrent course and is
associated with substantial economic costs due to increased healthcare utilization and productivity losses.
Interventions aimed at the prevention of recurrences may reduce patients' suffering and costs. Besides
antidepressants, several psychological treatments such as preventive cognitive therapy (PCT) are effective in the
prevention of recurrences of depression. Yet, many patients find long-term use of antidepressants unattractive, do
not want to engage in therapy sessions and in the primary care setting psychologists are often not available.
Therefore, it is important to study whether PCT can be used in a nurse-led self-help format in primary care. This
study sets out to test the hypothesis that usual care plus nurse-led self-help for recurrent depression in primary care
is feasible, acceptable and cost-effective compared to usual care only.
Design: Patients are randomly assigned to ‘nurse-led self-help treatment plus usual care’ (134 participants) or ‘usual
care’ (134 participants). Randomisation is stratified according to the number of previous episodes (2 or 3 previous
episodes versus 4 or more). The primary clinical outcome is the cumulative recurrence rate of depression meeting
DSM-IV criteria as assessed by the Structured-Clinical-Interview-for-DSM-IV- disorders at one year after completion of
the intervention. Secondary clinical outcomes are quality of life, severity of depressive symptoms, co-morbid
psychopathology and self-efficacy. As putative effect-moderators, demographic characteristics, number of previous
episodes, type of treatment during previous episodes, age of onset, self-efficacy and symptoms of pain and fatigue
are assessed. Cumulative recurrence rate ratios are obtained under a Poisson regression model. Number-needed-to-
be-treated is calculated as the inverse of the risk-difference. The economic evaluation is conducted from a societal
perspective, both as a cost-effectiveness analysis (costs per depression free survival year) and as a cost-utility
analysis (costs per quality adjusted life-year).
Discussion: The purpose of this paper is to outline the rationale and design of a nurse-led, cognitive therapy based
self-help aimed at preventing recurrence of depression in a primary care setting. Only few studies have focused on
psychological self-help interventions aimed at the prevention of recurrences in primary care patients.
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Recurrent major depressive disorder
Major Depressive Disorder (MDD) is a leading cause of
disease burden and is associated with significant health-
care costs and costs stemming from productivity losses
[1,2]. MDD’s disease burden stems largely from its re-
current nature [3]. Each additional depressive episode
increases the risk of recurrence by 18 % [4]. Interventions
aimed at the prevention of recurrences in recovered
patients may significantly reduce the burden of depression
[3]. Up till now, maintenance treatment has been largely
based on antidepressants (AD). However, the evidence-
base to support such prolonged treatment is poor [5-8]
and moreover there is no evidence when to stop AD since
most studies restricted their follow up to no longer than
2 years [9]. Furthermore, many depressed patients prefer
psychological treatments to drugs [10] and many are not
willing to take AD for prolonged periods of time [11,12].
Also, adherence in AD users is estimated at only 50 % at
best [11-13]. As such, there is a need for an accessible al-
ternative to maintenance treatment with AD. Psycho-
logical interventions might offer an interesting alternative
to prevent recurrence of MDD in recovered patients.
Terminology
At this point it might be well to introduce some termin-
ology. MDD tends to run a relapsing and recurrent course.
Both relapse and recurrence refer to the reappearance of a
full-blown MDD after a symptom-free period. The essen-
tial distinction between both terms is the time at which
each event occurs (Figure 1 [14]). According to the descrip-
tion by Frank et al. [15], relapse is defined as ‘a return of
symptoms satisfying full syndrome criteria for an episode
that occurs during a period of remission, but before recov-
ery’. As for recurrence, this is defined as ‘the appearance of
a new episode of MDD, occurring during recovery’. Con-
ceptually, this represents the beginning of a new episode ofFigure 1 Overview of response, remission, recurrence, and relapse in
(2009) [16] © 2009 Blackwell Munksgaardan illness. Treatment stages can be defined accordingly:
following remission and before recovery ‘continuation
treatment’ is offered. Following recovery, treatment enters
the maintenance stage. Both treatments have the aim to
prevent recurrences.
For research purposes a consensus definition recom-
mends that a 6-month threshold is justifiable to distinct
between remission and recovery because of the median
duration of MDD [15]. In patients experiencing relapsing/
recurring MDD however, this threshold can be debated
because of the mostly shorter duration of an episode. In
this trial no distinction is made between relapse and
recurrence (henceforth called ‘recurrence’) nor between re-
mission and recovery (henceforth ‘recovery’), nor between
continuation and maintenance treatment (henceforth
‘maintenance treatment’). Exact definitions and cut-off
points of all terms with respect to this trial are handled in
detail later (see ‘Eligibility of participants’).
Efficacy of psychological interventions
The literature shows that psychological interventions may
offer a good alternative or a welcome adjunct to AD.
Hollon et al. (2010) concluded in their review that Cogni-
tive Behavioural Therapy (and especially CT) is as effica-
cious as medications in the treatment of MDD and that
CT has an enduring effect that protects against subse-
quent relapse and possibly recurrence regardless of when
it is applied [17]. Continuation/maintenance CT has been
found to reduce risk for relapse/recurrence in MDD in a
trial of Jarrett et al. (2001) [18]. A meta-analysis by
Vittengl et al. (2007), including 28 studies and comprising
1,880 adults, demonstrated that among acute-phase treat-
ment responders, continuation of CBT compared to
assessment only or clinical management, reduced the num-
ber of recurrences substantially from 73 % to 40 %, over a
mean of 153 weeks follow-up [19]. Specific protocols based
on CBT have been developed for the prevention ofrelation to the treatment phase [14]. Modified after Tohen et al.
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For patients with a history of 4 or more depressive epi-
sodes, 75 % receiving PCT experienced a recurrence over a
period of 5,5 years versus 95 % receiving usual care [20].
PCT targets underlying cognitive vulnerability factors, such
as dysfunctional cognitions that are easily reactivated in
recovered patients and therefore may cause vulnerability
for recurrence. The treatment focuses on identifying and
changing these vulnerability factors, while at the same time
reinforcing specific memories of positive experience by
keeping a diary of positive experiences and formulating
specific recurrence prevention strategies [21].
The case for guided self-help
In the Netherlands, evidence-based psychological treat-
ments are less readily accessible in primary care [10]
because they require specific expertise, extensive training
and draw on scarce resources. Furthermore, reimburse-
ment of psychological treatments in primary care through
insurance is becoming limited. Because the vast majority
of persons with a high risk of developing a new episode
visits - and receives treatment from - their own primary
care physician (PCP), this seems to be the most appropri-
ate coordinator of preventive interventions [22]. These
interventions should be cost-effective, readily accessible at
the primary care or community level, acceptable for
patients and health care providers, and should easily be
integrated into current care.
Self-help interventions using self-help books (bibliother-
apy) are one of the most accessible forms of psychological
interventions for primary care patients. Research indicates
that self-help has a moderate to large effect in reducing
symptoms of depression and anxiety [23-26]. PCT can
easily be transformed into a self-help intervention because
of its structured design. Some form of support however,
should be provided to enhance patients' compliance, which
in turn is associated with better treatment response overall
[26-29]. There is growing evidence that mental health
nurses or social workers can effectively deliver self-help
treatment protocols for depression, particularly in chronic
care models [30,31]. For both economic and pragmatic rea-
sons it is attractive to let nurses play a pivotal and facilitat-
ing role in the provision of PCT instead of a psychologist.
Objectives
The primary objective of this study is to evaluate whether
nurse-led, cognitive treatment based self-help in addition
to usual care is cost-effective in preventing recurrences for
patients at high risk of recurrent MDD in primary care
compared to usual care alone. Furthermore, this study
examines whether the addition of nurse-led self-help to
usual care for patients with recurrent MDD is effective in
improving health related quality of life, in reducing co-
morbid distress, anxiety and/or somatisation, in improvingself-efficacy and meets with patients’ satisfaction. Finally,
we examine which socio-demographic and clinical vari-
ables (e.g. pain and fatigue) moderate treatment response.
Design
This study is a multi-site, pragmatic randomised controlled
trial among primary care patients with recurrent MDD
who are currently recovered. Patients are recruited through
primary care practices and are randomly assigned to two
parallel groups: ‘nurse-led self-help treatment plus usual
care’ (134 patients) or ‘usual care alone’ (134 patients). A
flowchart is shown in Figure 2. It is not possible to blind
neither patients nor healthcare providers to the interven-
tion in this study due to the nature of this self-help
intervention.
Eligibility of participants
Patients are eligible for participation in the trial when
they: 1) are between 18 and 65 years old, 2) have had at
least 2 previous depressive episodes 3) are currently
recovered, 4) are fluent in reading and speaking Dutch
and 5) have access to the internet. Criterion for ‘cur-
rently recovered’ includes ‘no diagnose of depression
according to the Structured Clinical Interview for DSM-
IV (SCID-I)’ [32]. The recovered episode should last for
longer than 8 weeks and no longer than 2 years.
Participants who have current (hypo) mania or a history
of bipolar disease, any current organic brain disorder,
psychotic disorder or severe sensory disabilities are
excluded. Patients who have drug or alcohol related abuse
or dependence as main diagnosis are also excluded. These
exclusion criteria are checked in patient files.
Recruitment
The PCP screens for eligible patients by searching the
database of the primary care practice using the following
indicators [33]: antidepressants prescription, strong free
text indication of depression or a history of depression
according to the International Classification of Primary
Care (ICPC) codes in the PCP’s patient files. Subse-
quently, the PCP approaches potentially eligible patients
with global information about the study, contact infor-
mation and a global screening form comprising three
questions: 1) did you experience 2 or more depressive
episodes? 2) are you currently recovered? and 3) did the
last episode end longer than 8 weeks- and no longer
than 2 years ago?. If a patient is eligible for the trial
based on the global screening and if the patient agrees
upon receiving more information, he is sent an extensive
study information letter and an informed consent form
for participation in the trial. Consenting patients are
assessed for their eligibility in more detail using the
SCID-I. Eligible patients who sign informed consent
enter the trial.
Search through databases from PC practices, employing a nurse                                                        
(search ‘ICPC codes for i.e. depression’, ‘antidepressants’ , ‘depression in free field’ , referral)
Eligible patients are sent a short information letter with response form
Interested patients reply and are sent an extensive information letter, response form  and informed consent
The SCID-1 is assessed for inclusion / exclusion criteria 
Did 1) patient meet full inclusion criteria and 2) sign informed consent?
Baseline measurements and randomisation
yes
UACUAC +pleh-fles del-esruN
Assessments (T = week 1-8 and month 3, 6, 9, 12 and 15 in both arms)
noexclude
Stratification variable;
no of previous episodes 
Interested patients reply by response form and signed informed consent
Figure 2 Flowchart.
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Self-help
The intervention consists of nurse-led self-help treat-
ment based on PCT [21,34]. Patients are offered a self-
help book including background literature for further
reading and assignments. This self-help book enables
patients to follow the treatment in the privacy of their
own homes and at a pace that suits them best. The treat-
ment consists of eight weekly modules with a fixed
structure and it takes approximately 1.5 hour each week
to complete the assignments. Additionally, patients fill
out the electronic Q-IDS-SR weekly to monitor the
severity of their depressive symptoms.
Nurse-led support
The nurse lends minimal support to help patients work
through the self-help intervention. Prior to the start of the
treatment, a face-to-face meeting with the nurse (with a
maximum duration of 30 minutes) is planned at the
primary care practice. This meeting involves a discussion
of current symptoms, motivational interviewing, psycho-
education on the course and treatment of recurrent
depression and an introduction to the nurse-led self-help
treatment on the basis of the self-help book. Afterwards,
the self-help treatment starts and eight weekly telephone
contacts (at a maximum of 15 minutes) follow, initiated
by the nurse. During these telephone contacts the nurse
explores how the patient fares with the self-help treatment
according to a strict protocol. In the weekly contacts thenurse asks the following questions: 1) did the patient fill
out the electronic Q-IDS-SR questionnaire? 2) did the
patient read and understand the literature belonging to
that week? 3) did the patient complete the accompanying
assignments? and 4) what difficulties did the patient
experience in his assignments? After answering these
questions, patients are shortly introduced to next week’s
literature and exercises. The contact is supportive, activat-
ing and facilitating and the nurse does not engage in a
therapeutic relationship with the patient. If a nurse notices
the emergence of depressive symptoms during a regular
phone-contact or a patient brings up feeling depressed,
the nurse emphasizes specific parts of the treatment that
may help the patient to better cope with these symptoms
in order to prevent recurrence. If a patient expresses sui-
cidal thoughts the PCP is notified immediately. After each
contact the nurse summarizes the conversation (including
the questions) in an electronic journal using a checklist.
This journal is a way to both monitor and promote treat-
ment integrity on the side of the patient (did the patient
read and apply the literature) and the nurse (did the nurse
go through all the questions).
Training and supervision of nurses
The mental health nurse attends an one-day training,
during which attention is paid to the protocol and content
of PCT and to guiding a self-help treatment. The nurse is
also taught to let recovered patients deal with symptoms.
Since participating nurses already have experience with
Table 1 overview of assessments
Measure Description T0 w1,8 T1 T2 T3 T4 T5
Interviews
SCID-I [32] DSM-IV Axis I
Disorders
+ + + + + +
Self-report measures
Q-IDS-SR [41] Depressive
symptoms
+ + + + + + +
EQ-5D [42] Quality of life + + + + + +
SF-12 [43] Quality of life + + + + + +
TIC-P [36] Direct/indirect
costs
+ + + + + +
4DSQ [44] Comorbid
psychopathology
+ + +
General self-
efficacy scale [45]
Self-efficacy + + +
FSS[46] Severity of fatigue +
MPQ-DLV[47] Severity/evaluation
of pain
+
MAQ [37] Medication
Adherence
+ + + + + +
CSQ-8 [48] Satisfaction +
T0 = baseline, w1,8 =week 1–8, T1 = 3 months, T2 = 6 months, T3 =9 months,
T4 = 12 months, T5 =15 months.
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training is delivered by two trained psychologist. To detect
adherence and/or competence issues, audiotaped telephone
contacts with two patients are evaluated during supervision
sessions for each nurse, before the actual start of the trial.
During the trial, nurses can contact their supervisors at any
time for additional questions and feedback.
Usual care
In both treatment conditions, treatment as usual involves
usual care (i.e. standard/routine treatment, including no
treatment) as typically provided by the PCP according to
the Dutch PCP clinical guidelines (NHG-guidelines) [35].
These guidelines recommend continuation of treatment
with AD, preventive psychological treatment or both,
depending on the distress, level of dysfunctioning, psycho-
logical or physical co-morbidity and preferences of the
patient.
In this trial, usual care is not restricted during the period
from entry to end of follow-up. By adding no restrictions to
usual care, the findings of this study are more generalisable.
There usually is some inter-practice variation in treatment
despite the clinical guidelines. It is therefore important to
obtain a clear understanding of what (additional) treat-
ments are received by patients in both arms of the trial. To
that end, data is collected on health care utilization, using
the TiC-P [36] – the most commonly used health care re-
ceipt interview in the Netherlands (see below for more
details on the measurements) and the Medication Adher-
ence Questionnaire (MAQ) [37]. As the use of usual care
in both arms in this trial brings the risk of behavioural
change by caregivers and patients because of the informa-
tion that is supplied [38], minimum information is supplied
to any participating person (see Discussion for further
details).
Sample size
To calculate the sample size of the intervention and control
group, we combined rudimentary findings from previous
randomised controlled trials (RCT’s), which resulted in a
mean recurrence rate of 33 % after 2 years of follow-up ver-
sus 67 % in the control group (active and non-active con-
trol). Based on this we assume a risk reduction of 20 % rate
in this study between the two conditions. To detect this
20 % risk reduction in a 2-sided test at alpha=0.05 and a
power of 1-beta=0.80, 107 patients in each condition are
required. Compensating for loss to follow-up of 20 % over
the whole 15 months follow-up, requires (107/0.8=) 134
participants at baseline in each trial arm.
Randomisation
Patients who are eligible for the trial and who have given
their informed consent, are randomised to ‘nurse-led self-
help treatment plus usual care’ or ‘usual care alone’. Anindependent researcher performs randomisation centrally
(Random Allocation Software version 1.0.0), using a
blocked randomisation scheme with blocks of 2 patients.
The researchers receive the participant’s number and auto-
matically random generated condition in the trial by email.
Randomisation is pre-stratified for the number of previous
depressive episodes (2 or 3 episodes versus 4 or more epi-
sodes). The rationale for stratification based on this variable
is that several subgroup analyses suggest that PCT is more
effective in ‘high risk’ patients, meaning patients with a his-
tory of 4 or more episodes on a lifetime basis [21,39,40].
Outcome measurements
For an overview of assessments at baseline, during the
intervention and during follow-up, see Table 1. The
primary researcher (KB) conducts collection and analysis of
the data with help of a research assistant (SK).
Demographics
At baseline the socio-demographic characteristics of partici-
pants are collected (age, gender, educational level, marital
status, etc.). The number and duration of previous depres-
sive episodes, age of onset of first depressive episode and
kind of treatments received are also assessed at baseline.
Primary outcome
The primary clinical outcome is the cumulative recur-
rence rate of depression meeting DSM-IV criteria for a
major depressive episode [49]. Recurrence of depression
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both arms with the SCID-I [32] at 3, 6, 9, 12 and 15 months
follow-up by a trained researcher and research assistant.
Interviews are randomly audiotaped and evaluated for in-
tegrity reasons. The incidence rate in the intervention
group is compared to the incidence rate in the control
group and thus expressed as the (cumulative) incidence rate
ratio.
Secondary outcomes
Secondary clinical outcomes include health related quality
of life (measured with both the ‘EuroQol’ (EQ-5D)[42]
and ‘Short Form-12’ (SF-12)[43]), severity of depressive
symptoms (measured with the Q-IDS-SR [41]), co-morbid
distress, anxiety and somatisation (measured with the
‘Four Dimension Symptom Questionnaire’, 4-DSQ [44])
and self-efficacy (measured with the ‘General Self Efficacy
Scale’, GSES [45]). Quality adjusted life years (QALY’s) are
calculated based on both the EuroQol [42] and SF-12 [43],
using the Dutch tariff estimated by Lamers et al. [50] and
using Brazier’s algorithm [51], respectively. All secondary
clinical outcomes are measured at baseline and at 9 and
15 months follow-up.
Putative effect-moderators
Several risk factors for recurrent depression have been
identified [52] and may also be relevant for predicting treat-
ment response. These risk factors include non-adherence,
demographic factors such as age and gender, high number
and longer duration of previous episodes, younger age at
the onset of the first depressive episode [53], presence of
residual symptoms [54], low socioeconomic status [55], low
self-efficacy for managing depression [55] and also symp-
toms of pain [56] and fatigue [57] appear to be risk indica-
tors for imminent recurrence of depression. The type of
treatment received during previous depressive episodes
(psychological intervention/AD/no care) may also be
relevant for treatment response. Patients who already had a
psychological intervention may have the benefit of possible
long-term protection for recurrence [58]. All of these
factors are therefore assessed as putative effect-moderators.
Cost measures
Cost-effectiveness is evaluated from a societal perspective
meaning that the costs of the intervention, other health
care utilization costs, patients' out-of-pocket costs and costs
due to productivity losses are included in the economic
evaluation. Health care utilization is measured using the
TiC-P [36] at baseline and 3, 6, 9, 12 and 15 months fol-
low-up. Medical costs that are assessed include costs
related to the intervention, medication use, hospital admis-
sions, and contacts with other healthcare professionals. For
the valuation of health care utilization, standard prices pub-
lished in the Dutch costing guidelines are used [59].Medication use is valued using prices of the Royal Dutch
Society for Pharmacy, including the costs of prescription by
the PCP and the pharmacist’s dispensing costs. A cost price
for the nurse-led self-help intervention is calculated using
a bottom-up approach and will account for costs for
personnel, patient materials and rental of practice spaces.
Costs and effects exceeding 12 months follow-up are dis-
counted, in accordance with the Dutch guideline for eco-
nomic evaluation in health care [60]. Costs of productivity
losses are estimated using the friction cost method [61]. In
a secondary analysis, the human capital method is used to
estimate productivity losses.
Analyses of clinical outcomes
Standard descriptive methods (e.g. frequencies, percentages
and means) are used to summarize the demographic and
clinical features of the intervention and control group and
to check whether the randomisation has resulted in a well-
balanced design.
Analyses are conducted according to the intention-to-
treat principle, meaning that all patients who have been
randomised are included in the analyses. Missing endpoints
are imputed using the Expectation-Maximization (EM)
algorithm. To gauge the robustness of the outcomes, this
analysis is repeated while using a Multiple-Imputation (MI)
approach. All tests are conducted at P <0.05, 2-tailed.
Additional completer analyses for all patients that attended
at least 80 % of the telephone sessions are performed.
Analysis of primary outcome
Cumulative recurrence rate ratios are estimated using a
Poisson regression model. Number-needed-to-be-treated
(NNT) is calculated as the inverse of the risk difference
(RD) which is estimated using a linear probability model.
Data-analysis takes into account that data are clustered
within primary care practices and patients. The nested data
structure entails violation of the usual assumption that data
are uncorrelated. Therefore, all analyses are design-based,
taking the clustered data structure into account, using Sta-
ta’s [62] procedures for clustered data [63].
Analysis of secondary outcomes
The effect of the self-help treatment on health related qual-
ity of life, symptom severity, co-morbid distress, anxiety
and/or somatisation and self-efficacy is analysed by regres-
sing these secondary endpoints with the randomisation
condition, while correcting for baseline values.
Analysis of effect-moderation
Moderator analyses are conducted for socio-demographic
and clinical variables. Subgroups that show particularly
good response to the intervention are identified by regres-
sing (P< 0.05) depression severity (measured with Q-IDS-
SR) on the interaction term of treatment and baseline
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depressive episodes, previous and current treatment, age
of onset of first depression, self-efficacy in managing de-
pression, symptoms of pain and fatigue and socio-
demographic characteristics like gender, marital status,
age and socio-economic status.
Analysis of economic data
Missing cost- and effect data are imputed using multiple
imputation according to the MICE algorithm developed
by van Buuren [64]. Costs typically have a highly skewed
distribution. Policy makers want to have information on
the difference in mean total costs between the two treat-
ment groups in order to estimate the total health care
budget needed for a specific condition [65]. Therefore,
bias-corrected and accelerated bootstrapping with 5000
replications is used to estimate 95 % confidence intervals
around the mean difference in total costs between the
treatment groups.
Both a cost-effectiveness analysis (CEA, with depression-
free person years as the clinical end term) and as a cost-
utility analysis (CUA, with incremental costs per quality
adjusted life years (QALY) gained as the clinical end-term)
are performed. Bootstrapping is used to estimate the
uncertainty surrounding the incremental cost-effectiveness
ratios (ICERs) which are graphically presented on cost-
effectiveness planes. Cost-effectiveness acceptability curves
and net monetary benefits are also estimated [66].
An incremental net benefit regression (INBR) analysis
is conducted to address the research question in which
groups the intervention is likely to be particularly cost-
effective, analogous to the moderator analyses for
clinical endpoints. The same set of variables is used in
these INBR analyses. The incremental net benefit is
calculated as Eλ – C. The first term is the number of
units of effectiveness gained in the intervention group in
comparison with the control group multiplied by the
amount (λ) society is willing to pay (WTP) for a unit of
effect gained. Because λ is unknown, we use a likely
WTP-range. The product term is subtracted by the
difference in costs between the groups yielding the net
benefit expressed in monetary terms. Incremental net-
benefits are analysed using a regression analysis ap-
proach [67] and helps to identify sub-groups for which
the intervention is particularly cost-effective.
Patients’ satisfaction
At 15 months patients’ satisfaction is assessed using the
Client Satisfaction Questionnaire (CSQ-8) [48] in both
the intervention and control group. Additionally, 20
‘experimental’ patients who responded best, and 20
‘experimental’ patients who responded worst in terms of
recurrences are approached for an in-depth (qualitative)
interview. Comparing responses from both groups mayhelp to increase understanding what aspects of the inter-
vention must change or remain intact.
Discussion
Given its recurrent character, new minimal interventions
are needed to prevent new episodes of MDD. As
patients with recurrent MDD account for great societal
costs, an intervention to prevent recurrence in the main-
tenance phase will potentially lead to great reduction in
health care utilization and costs of absenteeism and
presenteeism. This is as far as we are aware of, the first
study that examines the cost-effectiveness of a nurse-led,
cognitive treatment based self-help for patients with
recurrent MDD in primary care. This innovative self-
help format ensures that patients can complete the treat-
ment in their own time and at their own homes, which
makes it easy accessible. Besides, being led by nurses,
the treatment is expected to be economically affordable
and sustainable.
The effect of several socio-demographic and clinical
variables on treatment response is assessed. This might
lead to insights that will lead to the development of more
targeted interventions.
The RCT-design of this trial is considered the ultimate
test of a medical hypothesis, and is the support of
evidence-based medicine. By adding no restrictions to
usual care in this RCT, the findings of this study will be
more generalisable.
Risks for adverse events in patients in the intervention
arm are very low due to the psychological character of
the intervention and because there is no restriction to
usual care. In the case of a patient expressing suicidal
thoughts, the PCP is notified. These procedures are
made explicit in the informed consent papers and
protocols.
A limitation of this trial is that there might not be a big
contrast in primary outcome (cumulative rate of recur-
rence) between the 2 arms of the trial at the end of
follow-up, because both arms include usual care. Another
limitation is, as in any trial that involves psychological
treatment, that it is not possible, due to the design of the
intervention, to blind patients, health care providers and
researchers to the patient’s randomised condition. There-
fore it is not possible to prevent any behavioural change
during the course of the trial. Patients’ behaviour in the
control arm might be influenced by reading the study
information letter and a PCP’s choice regarding usual care
might be influenced by the knowledge of a patient starting
the intervention. Nurses might be influenced in their
support for patients when guiding the self-help treatment
because of their knowledge of the patients’ additional care.
The information given to PCP’s, nurses and patients in
both arms is therefore limited to a minimum to overcome
this limitation.
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